Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
Launched by KYTHERA BIOPHARMACEUTICALS · Jun 6, 2014
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No study medication was administered in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any subject who successfully completed a Kythera-sponsored clinical trial of ATX-101 (06-03, 07-07, 09-15)
- • Signed informed consent
- • Willingness to comply with schedule and procedures of the study
- Exclusion Criteria:
- • Subjects who have had or are undergoing treatment that may affect the evaluation of the submental area will be excluded
About Kythera Biopharmaceuticals
Kythera Biopharmaceuticals is a clinical-stage biotechnology company dedicated to the development of innovative aesthetic treatments that enhance the quality of life for patients. Focused on addressing unmet needs in the aesthetic medicine market, Kythera leverages advanced scientific research and technology to create targeted therapies. With a commitment to rigorous clinical trials and regulatory standards, the company aims to deliver safe and effective solutions that empower individuals to achieve their desired appearance. Through its expertise in biopharmaceutical development, Kythera is poised to make significant contributions to the field of aesthetic medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fridley, Minnesota, United States
Plano, Texas, United States
Omaha, Nebraska, United States
Birmingham, Alabama, United States
Chestnut Hill, Massachusetts, United States
Saint Louis, Missouri, United States
Oakville, Ontario, Canada
Beverly Hills, California, United States
Beverly Hills, California, United States
San Francisco, California, United States
Naperville, Illinois, United States
Sydney, New South Wales, Australia
Benowa, Queensland, Australia
Carina Heights, Queensland, Australia
South Yarra, Victoria, Australia
Niagara Falls, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Salford, Manchester, United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Frederick Beddingfield, III, MD, PhD
Study Director
Sponsor GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials